Comparison of Survival Between Patients with Hepatocellular Carcinoma Beyond the “Up-to-7” Criterion Who Received Adjuvant PD-1 Inhibitors or Active Surveillance: A Target Trial Emulation Study
The IMbrave050 trial suggested that adjuvant immune checkpoint inhibitor therapy may benefit patients with hepatocellular carcinoma exceeding the “up-to-7” criterion. This study aimed to compare survival outcomes and safety between such patients receiving adjuvant programmed cell death protein 1 inhibitors and those undergoing active surveillance after curative resection.
Authors
- Jia‐Yong Su (ORCID: https://orcid.org/0000-0002-0960-5394)
- Ze Su (ORCID: https://orcid.org/0009-0000-1360-0783)
- Mei-lan Huang
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Da-Long Yang (ORCID: https://orcid.org/0000-0002-2931-1166)
- Pingping Guo (ORCID: https://orcid.org/0000-0002-5091-9387)
- Kang Chen (ORCID: https://orcid.org/0000-0003-0745-7946)
- Zhicheng Li (ORCID: https://orcid.org/0000-0003-4140-0580)
- Xiaoling Xu (ORCID: https://orcid.org/0000-0002-7472-0495)
- Pei‐Sheng Wu
- Jun‐Jie Ou (ORCID: https://orcid.org/0009-0003-2700-1118)
- Yi-Li Ma
- Wen-Hai He
- Shao-Ping Liu
- Rong-Rui Huo
- Fu-Quan Yang
- on behalf of the GUIDANCE investigators
- Wen-Ting Li
- Lei-Po Lin
- Zhi-Hao Huang
- Shu-Chang Chen
- Hang Su
- Zhen Liu
- Wen-Ting Chen
- Jian-Rong Li
- Min Luo
- Bei-Bei Long
- Tai-Xin Yang
- Ning Peng
- Liang Ma
- Xiao-Feng Dong
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2026-09-24
- DOI
- https://doi.org/10.14218/jcth.2026.00283
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00